Dizal (Jiangsu) Pharmaceutical Co. Ltd. A
Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269… Read more
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) - Net Assets
Latest net assets as of June 2025: CN¥1.63 Billion CNY
Based on the latest financial reports, Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) has net assets worth CN¥1.63 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.22 Billion) and total liabilities (CN¥1.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.63 Billion |
| % of Total Assets | 50.61% |
| Annual Growth Rate | -14.98% |
| 5-Year Change | -81.46% |
| 10-Year Change | N/A |
| Growth Volatility | 92.52 |
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥200.06 Million | -76.43% |
| 2023-12-31 | CN¥848.63 Million | -51.74% |
| 2022-12-31 | CN¥1.76 Billion | -28.60% |
| 2021-12-31 | CN¥2.46 Billion | +128.27% |
| 2020-12-31 | CN¥1.08 Billion | +139.54% |
| 2019-12-31 | CN¥450.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 271450947499.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥3.55 Billion | 1833.89% |
| Total Equity | CN¥193.76 Million | 100.00% |
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Dizal (Jiangsu) Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ladder Capital Corp. Cl A
LSE:0JSZ
|
$1.12 Billion |
|
Jamf Holding
NASDAQ:JAMF
|
$1.13 Billion |
|
Xior Student Housing NV
PINK:XIORF
|
$1.13 Billion |
|
DBV Technologies
NASDAQ:DBVT
|
$1.13 Billion |
|
Hufvudstaden AB ser. A
LSE:0GW3
|
$1.12 Billion |
|
CENERGY HLDGS NOM.
F:9CN
|
$1.12 Billion |
|
Fugro N.V.
AS:FUR
|
$1.12 Billion |
|
PROS Holdings Inc
NYSE:PRO
|
$1.12 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 848,627,416 to 193,755,800, a change of -654,871,615 (-77.2%).
- Net loss of 845,956,286 reduced equity.
- Dividend payments of 20,553,670 reduced retained earnings.
- Other factors increased equity by 211,638,341.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-845.96 Million | -436.61% |
| Dividends Paid | CN¥20.55 Million | -10.61% |
| Other Changes | CN¥211.64 Million | +109.23% |
| Total Change | CN¥- | -77.17% |
Book Value vs Market Value Analysis
This analysis compares Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 103.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 38.55x to 103.96x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.25 | CN¥48.23 | x |
| 2020-12-31 | CN¥3.00 | CN¥48.23 | x |
| 2021-12-31 | CN¥6.09 | CN¥48.23 | x |
| 2022-12-31 | CN¥4.32 | CN¥48.23 | x |
| 2023-12-31 | CN¥2.08 | CN¥48.23 | x |
| 2024-12-31 | CN¥0.46 | CN¥48.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dizal (Jiangsu) Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -436.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -235.05%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 8.87x
- Recent ROE (-436.61%) is below the historical average (-131.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -98.97% | -1086.74% | 0.07x | 1.39x | CN¥-490.79 Million |
| 2020 | -54.37% | -2113.09% | 0.02x | 1.13x | CN¥-694.50 Million |
| 2021 | -27.20% | -6512.85% | 0.00x | 1.11x | CN¥-916.16 Million |
| 2022 | -41.85% | 0.00% | 0.00x | 1.18x | CN¥-911.85 Million |
| 2023 | -130.53% | -1213.42% | 0.06x | 1.76x | CN¥-1.19 Billion |
| 2024 | -436.61% | -235.05% | 0.21x | 8.87x | CN¥-865.33 Million |
Industry Comparison
This section compares Dizal (Jiangsu) Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) | CN¥1.63 Billion | -98.97% | 0.98x | $1.12 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |